ten23 health & Becton Dickinson partner on full-service wearable injector commercialization

ten23 health, the human-centric and sustainable strategic CDMO partner of choice for the pharmaceutical industry and biotech start-ups today announced a manufacturing collaboration to support the commercialization of the BD Libertas wearable injector. The collaboration will offer biopharma companies supply chain readiness of a fully integrated, ready-to-use solution for the subcutaneous delivery of large-volume drugs, helping speed development and reduce risk in complex injectable programs.

The collaboration includes the BD Libertas wearable injector with a 5 ml or 10 ml BD glass cartridge, supported by ten23 health’s process development, aseptic filling, assembly, and quality control services. This setup enables pharmaceutical partners to leverage the BD Libertas wearable Injector platform and ten23 development and manufacturing services to bring high-volume subcutaneous treatments to the clinic and market, maintaining flexibility and adequate patient usability.

ten23’s recently announced Line 0 will enable Pharmaceutical Customers to test cartridge compatibility, perform stability studies, and optimize filling and stopper setting processes under fully representative conditions, without the delays or costs of GMP production. This enables a faster and more informed path to scale-up.

The BD Libertas Wearable Injector offers a ready-to-use, wearable injector for subcutaneous administration of high-dose biologics—enabling pharma to transition biologics from IV to SC delivery with potential for a positive patient experience. By combining BD platform technology with ten23 integrated services, BD and ten23 health aim to enable supply chain readiness to support commercialization and support smoother regulatory pathways.

“Enabling successful patient treatment on behalf of our customers is a key priority for ten23. Based on the already successful collaboration of ten23 with BD for the BD iDFil  solution (RFID-enabled PFS/containers), we are happy to expand our collaboration to also include BD Libertas Wearable Injector platform Our unique offerings and experiences with a range of devices make ten23 an ideal partner for any SC delivery options”, says Prof. Dr. Hanns-Christian Mahler, Chief Enablement Officer at ten23 health.